pharmaceutical investing CMS Grants Progenics New Technology Add-On Payment for Inpatient Use of AZEDRA
pharmaceutical investing Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy
pharmaceutical investing Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration
pharmaceutical investing Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility
pharmaceutical investing Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer
SAGA Metals Completes Phase 2 of Major Drill Program at the Radar Project in Labrador-Confirms Extensive Oxide Mineralization in All Drill Locations at Trapper North and South Zones & Provides Corporate Update
ReeXploration Announces Field Program Results Confirming Large-Scale Uranium Target at Eureka, Namibia
